On Friday, Jan. 25, AbbVie ABBV will report its last quarter's earnings. Here is Benzinga's take on the company's release.
Earnings and Revenue
Wall Street analysts see AbbVie reporting earnings of $1.93 per share on revenue of $8.37 billion.
In the same quarter last year, AbbVie reported EPS of $1.48 on revenue of $7.74 billion. If the company were to match the consensus estimate, earnings would be up 30.41 percent. Sales would be up 8.15 percent from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
EPS Estimate | 2.01 | 1.97 | 1.79 | 1.44 |
EPS Actual | 2.14 | 2 | 1.87 | 1.48 |
Stock Performance
Over the last 52-week period, shares are down 16.94 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on AbbVie stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
AbbVie's Q4 conference call is scheduled to begin at 9:00 a.m. ET and can be accessed here: https://edge.media-server.com/m6/p/4d82gmvv
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.